iCAD (ICAD) – Company Press Releases
-
iCAD Releases Enhanced ProFound Detection Workstation Features to Streamline Mammogram Interpretation for Radiologists
-
iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results
-
iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings
-
iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)
-
iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
-
iCAD to Participate in the BTIG at Snowbird: 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
-
iCAD Expands Board of Directors with Appointment of Michael J. Doyle, FACHE as New Board Member
-
iCAD Expands Executive Sales Leadership Team as Business Grows
-
iCAD’s AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare
-
iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease
-
iCAD and CancerIQ Announce Partnership to Integrate AI-Enabled Technology With Best-in-Class Risk Assessment and Care Management Platform Offering A Comprehensive Breast Health Care Solution
-
iCAD to Participate in the 14th Annual Craig-Hallum Alpha Select Conference
-
iCAD Reports Financial Results for Third Quarter Ended September 30, 2023
-
iCAD to Report Third Quarter 2023 Financial Results on November 13, 2023
-
iCAD, Inc. Announces Sale of Xoft, its Brachytherapy Business Line, to Elekta
-
Health Canada Grants Device License for iCAD's ProFound Risk 2.0, Revolutionizing Breast Cancer Risk Via a 1-2 Year Assessment
-
iCAD Reports Financial Results for Second Quarter Ended June 30, 2023
-
iCAD and Google Health Expand Integration of Google’s AI Technology with iCAD’s ProFound Breast Health Suite for 2D Mammography for Use as Independent Reader
-
iCAD to Report Second Quarter 2023 Financial Results on August 14, 2023
-
iCAD Signs Strategic Commercial Agreement with Radiology Partners, the Nation’s Largest Radiology Practice
-
iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Cleveland Clinic
-
iCAD Offers ROI Analysis Based on Real-World Results from its ProFound Breast AI Suite at AHRA Annual Meeting
-
iCAD’s ProFound AI Breast Suite Wins U.S. General Services Administration’s AI Healthcare Challenge Award
-
iCAD Reports Financial Results for First Quarter Ended March 31, 2023
-
New Long-Term Real-World Research Confirms Xoft Skin eBx is as Safe and Effective as Mohs Surgery
-
iCAD to Report First Quarter 2023 Financial Results on May 15, 2023
-
iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Boca Raton Regional Hospital
-
New and Real-World Clinical Evidence Confirms ProFound AI Increases Cancer Detection without Increasing the Rate of Recalls and Reveals Critical Clues to Inform Clinical Decisions
-
iCAD Strengthens Leadership Team with Appointment of Chief Financial Officer and New Senior Executives
-
ProFound AI Risk Outperforms Traditional, Widely-Accepted Breast Cancer Risk Models for Both Short-term and Long-term Risk Assessments
-
iCAD Reports Financial Results for Fourth Quarter ended December 31, 2022 and Year End
-
iCAD’s Breast AI Suite Empowers Customers to Lead the Way in Support of FDA’s National Breast Density Reporting Standard
-
iCAD Previews Fourth Quarter Financial Results, Full Report on March 28, 2023
-
iCAD Announces Leadership Transition
-
New Real-World Clinical Evidence Confirms ProFound AI Boosts Radiologists’ Efficiency and Accuracy
-
iCAD to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
-
iCAD Announces CFO Transition and Hires New Senior Vice President, US Commercial Sales, AI
-
iCAD Announces Board of Directors Transition
-
iCAD features Solis Mammography in upcoming “ProFound Insights, ProFound Impact” webinar
-
iCAD and Google Health Ink Strategic Development and Commercialization Agreement
-
Positive New Research Presented at RSNA 2022 Reaffirms iCAD’s Breast AI Suite Improves Radiologists’ Performance and Breast Cancer Detection
-
iCAD to Participate in the 13th Annual Craig-Hallum Alpha Select Conference
-
iCAD to Present at HLTH 2022 With Google
-
iCAD Reports Financial Results for Third Quarter Ended September 30, 2022
-
iCAD to Join Forces with Radiology Partners, the Nation’s Largest Radiology Practice
-
iCAD to Report Third Quarter 2022 Financial Results on November 10, 2022
-
iCAD and Solis Mammography Ink Deal to Collaborate on Use of AI to Evaluate Risk of Cardiovascular Disease
-
iCAD To Participate in The Lake Street Capital Markets 6th Annual Best Ideas Growth (BIG6) Conference on September 14, 2022
-
iCAD Customers in the U.S. and Europe Increasingly Adopting Company’s Full Suite of Breast AI Technologies via Subscription Model
-
iCAD Reports Financial Results For Second Quarter 2022
Back to ICAD Stock Lookup